Linagliptin

Chemical formula: C₂₅H₂₈N₈O₂  Molecular mass: 472.542 g/mol  PubChem compound: 10096344

Therapeutic indications

Linagliptin is indicated for:

Type 2 diabetes mellitus

Population group: only adults (18 years old or older)

Linagliptin is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:

  • Monotherapy
    • when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
  • Combination therapy
    • in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: TRAJENTA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈